Mabvax Therapeutics Holdings Inc Share Price Nasdaq
Equities
US55414P7024
Biotechnology & Medical Research
Sales 2016 | 1L 1.24Cr | Sales 2017 | - | Capitalization | 1.44Cr 120.38Cr |
---|---|---|---|---|---|
Net income 2016 | -1.7Cr -142Cr | Net income 2017 | -1.9Cr -158.7Cr | EV / Sales 2016 | 147 x |
Net Debt 2016 | 5L 3.93Cr | Net Debt 2017 | 24.81L 21Cr | EV / Sales 2017 | - |
P/E ratio 2016 |
-0.93
x | P/E ratio 2017 |
-0.25
x | Employees | - |
Yield 2016 * |
-
| Yield 2017 |
-
| Free-Float | 92.02% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 72 | - | |
Chief Tech/Sci/R&D Officer | 81 | 08/14/08 | |
Paul W. Maffuid
CTO | Chief Tech/Sci/R&D Officer | 68 | 08/14/08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Tech/Sci/R&D Officer | 81 | 08/14/08 |
1st Jan change | Capi. | |
---|---|---|
+16.59% | 12TCr | |
+21.66% | 12TCr | |
+22.18% | 2.7TCr | |
-21.45% | 2.04TCr | |
-16.89% | 1.64TCr | |
-17.98% | 1.59TCr | |
-44.74% | 1.56TCr | |
+62.24% | 1.49TCr | |
+3.56% | 1.36TCr |